A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis

Zhao, Shuai; Tian, Run; Wu, Jun; Liu, Shaoli; Wang, Yuanning; Wen, Meng; Shang, Yingxu; Liu, Qing; Li, Yan; Guo, Ying; Wang, Zhaoran; Wang, Ting; Zhao, Yujing; Zhao, Heng; Cao, Hui; Yu, Shaohua; Sun, Jiashu; Jiang, Qiao; Ding, Baoquan

doi:10.1038/s41467-020-20638-7

Cited by 90 publications

(86 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aptamers have attracted attention in targeted therapy because of their high binding affinity toward specific targets such as proteins, cells, small molecules, and even metal ions, antibodies for which are difficult to obtain Most importantly, the complementary sequences of aptamer could be utilized as antidote. Once there have generated obvious effects caused by aptamers, after injection of their complementary sequences, they could form double-strands immediately and destroy three-dimensional structure of aptamers (Krissanaprasit, 2021 ; Tabuchi, 2021 ; Zhao et al, 2021 ). Thus, in this study, to solve side effects caused by CD123 targeted molecules, we tried to assess whether complementary sequence of SS30 could alleviate cytokine storm caused by SSFH.…”

Section: Discussionmentioning

confidence: 99%

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy

Zhang

Zhu

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

CD123 targeting molecules have been widely applied in acute myelocytic leukemia (AML) therapeutics. Although antibodies have been more widely used as targeting molecules, aptamer have unique advantages for CD123 targeting therapy. In this study, we constructed an aptamer hydrogel termed as SSFH which could be precisely cut by Cas9/sgRNA for programmed SS30 release. To construct hydrogel, rolling-circle amplification (RCA) was used to generate hydrogel containing CD123 aptamer SS30 and sgRNA-targeting sequence. After incubation with Cas9/sgRNA, SSFH could lose its gel property and liberated the SS30 aptamer sequence, and released SS30 has been confirmed by gel electrophoresis. In addition, SS30 released from SSFH could inhibit cell proliferation and induce cell apoptosis in vitro . Moreover, SSFH could prolong survival rate and inhibit tumor growth via JAK2/STAT5 signaling pathway in vivo . Additionally, molecular imaging revealed SSFH co-injected with Cas9/sgRNA remained at the injection site longer than free aptamer. Furthermore, once the levels of cytokines were increasing, the complementary sequences of aptamers injection could neutralize SS30 and relieve side effect immediately. This study suggested that CD123 aptamer hydrogel SSFH and Cas9/sgRNA system has strong potential for CD123-positive AML anticancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy

Zhang

Zhu

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

show abstract

“… 62 Origami can also mark molecular beacons or aptamers for biosensing and tumor treatment. 63,64 Ding et al 60 used DNA origami as a template to assemble thrombin-bound aptamers with precise nano-spatial control ( Fig. 4C ).…”

Section: Dna Nanostructure-based Nucleic Acid Probesmentioning

confidence: 99%

DNA nanostructure-based nucleic acid probes: construction and biological applications

Wang

et al. 2021

Chem. Sci.

103

View full text Add to dashboard Cite

show abstract

“…In addition, neutralizing aptamers can be easily and rapidly produced by chemical synthesis without batch-to-batch differences. [12][13][14] However, as monomers, neutralizing aptamers cannot ensure simultaneous binding of the three RBD S on the trimeric-spike, resulting in unsatisfactory therapeutic application.…”

Section: Mainmentioning

confidence: 99%

Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection

Sun¹,

S²,

Song³

et al. 2021

Preprint

View full text Add to dashboard Cite

New neutralizing agents against SARS-CoV-2 and the associated mutant strains are urgently needed for the treatment and prophylaxis of COVID-19. Herein, we develop a spherical cocktail neutralizing aptamer-gold nanoparticle (SNAP) to synergistically block the interaction of SARS-CoV-2 receptor-binding domain (RBD) and angiotensin-converting enzyme-2 (ACE2). Taking advantage of the simultaneous recognition of multi-homologous and multi-heterogenous neutralizing aptamers and dimensionally matched nano-scaffolds, the SNAP exhibits increased affinity to the RBD with a dissociation constant value of 5.46 pM and potent neutralization against authentic SARS-CoV-2 with a half-maximal inhibitory concentration of 142.80 aM. Additional benefits include the multi-epitope blocking capability of the aptamer cocktail and the steric hindrance of the nano-scaffold, which further covers the ACE2 binding interfaces and affects the conformational transition of the spike protein. As a result, the SNAP strategy exhibits broad neutralizing activity, almost completely blocking the infection of<a> N501Y</a> and D614G mutant strains. Overall, the SNAP strategy provides a new direction for development of anti-virus infection mechanisms, both to fight the COVID-19 pandemic and serve as a powerful technical reserve for future unknown pandemics.

show abstract

A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis

Cited by 90 publications

References 41 publications

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy

DNA nanostructure-based nucleic acid probes: construction and biological applications

Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection

Contact Info

Product

Resources

About